SCHEMBL25188913

SCHEMBL25188913

C#CCOc1ccc2c(=O)cc3oc4cc(N(CC)CC)ccc4nc-3c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCP2 P22307 1/20 0.71
MEN1 O00255 1/20 0.66
NPC1 O15118 1/20 0.66
POLB P06746 1/20 0.66
RAB9A P51151 1/20 0.66
KMT2A Q03164 1/20 0.66
GPR84 Q9NQS5 10/20 0.49
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
CYP1A1 P04798 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAOB P27338 2/20 0.39
IGLV6-57 P01721 1/20 0.39
CA12 O43570 2/20 0.39
CA4 P22748 2/20 0.39
CA9 Q16790 2/20 0.39
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19646592 0.89 SCP2 (0.77) SCP2MEN1NPC1POLBRAB9A
SCHEMBL16812947 0.88 SCP2 (0.74) SCP2MEN1NPC1POLBRAB9A
SCHEMBL62370 0.86 SCP2 (0.77) SCP2MEN1NPC1POLBRAB9A
SCHEMBL26434823 0.85 SCP2 (0.76) SCP2MEN1NPC1POLBRAB9A
SCHEMBL3501312 0.85 SCP2 (0.82) SCP2MEN1NPC1POLBRAB9A
SCHEMBL26434988 0.84 SCP2 (0.75) SCP2MEN1NPC1POLBRAB9A
SCHEMBL14267417 0.83 SCP2 (1.00) SCP2MEN1NPC1POLBRAB9A
SCHEMBL17230446 0.82 MEN1 (0.67) SCP2MEN1NPC1POLBRAB9A
SCHEMBL13201656 0.81 SCP2 (0.76) SCP2MEN1NPC1POLBRAB9A
SCHEMBL7812704 0.81 SCP2 (0.93) SCP2MEN1NPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009659-A1 DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS ÉCOLE NATIONALE SUPÉRIEURE DE CHIMIE DE RENNES (FR) 2025-01-09 US disclosed
EP-4433449-A1 DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS Université de Rennes (FR) 2024-09-25 EP disclosed
WO-2023083983-A9 DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS UNIVERSITE DE RENNES (FR) 2024-07-18 WO disclosed
WO-2023083983-A1 DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS UNIVERSITE DE RENNES (FR) 2023-05-19 WO disclosed
EP-4180410-A1 DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS Université de Rennes (FR) 2023-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009659-A1 DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS LCAT, FNTA, LIPA SCP2 244/4885MEN1 3847/4885NPC1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.